TP53 and neoplasm: More than 50% of patients resistant to lorlatinib have been found to harbor a TP53 mutation, and in the ALTA-1L trial, circulating tumor DNA (ctDNA) analysis found that in 37% with a TP53 mutation at diagnosis, PFS was inferior with both brigatinib and crizotinib as compared to patients with TP53 wild-type tumor (51, 76).